fda compounding semaglutide warning letters news Last month, the issued 25 to telehealth companies over what it called false or misleading claims about compounded GLP-1 medications. Read more at the link in the comments below GLP-1 Compounding: When Innovation May

However, Retatrutide is not yet available, and we suggest consulting with a healthcare provider in Skokie to explore current medications that can support your weight loss goals

This product is not intended for the treatment of Type 1 Diabetes

sounds dumb but its nice Karen D., 52, Montreal QC Weeks 25-36 Summary: Patience Pays Off Weight loss: 4-8 pounds this period (42-46 pounds total, ~21% of starting weight) Weekly loss rate: Averages 0.3-0.7 pounds weekly (significantly slower but still progressing) Body composition: Often improving more than scale suggests Discontinuation rate: 2-3% stop during this period, usually from frustration with slowing progress Psychological state: Requires intentional perspective maintenance Key achievement: Persisting through plateau without giving up or making counterproductive changes Weeks 37-48: The Plateau Phase (12mg Maintenance) Starting Weight Week 37: ~174 pounds | Expected Weight Week 48: 167-171 pounds | Net Loss This Period: 3-7 pounds | Total Loss: 49-53 pounds Whats Happening Physiologically Approaching maximum effect of Retatrutide at 12mg weekly dose

Furthermore, a multinational cohort study involving five countries revealed that neither insulin detemir nor insulin glargine significantly increases cancer risk compared to human insulin [107]